IMNM
Immunome Inc.
$23.61
+2.12 (+9.87%)
At close · Jul 2
Market Cap
$2.67B
Shares
113,250,394
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.61
Open$21.60
Day$21.26–23.67
52W$7.96–27.65
Avg vol 30d1.5M
Short int18.1M · 16.0% float · 12.9d
Short vol72%
Last earningsMay 12, 2026
DataOct 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+19% above
+
Price vs 50-day avg
+12% above
−
RSI (14)
72 · overbought
+
MACD trend
positive
◦
52-week position
79% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $21 › 200d $20 — 50d above 200d
+
Institutional flow
+8% holders QoQ · +47 funds added
+
Insider flow
Net +$103.9K over 90 days · 50% sells
−
Short interest
16.03% of float · ▲ +7.6% MoM · 12.9 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
200 holders — near 3-yr high, broad support
Fundamentals
Fair
−
Revenue growth
−23% Y/Y
+
EPS growth
+51% Y/Y
−
Free cash flow
$-200.6M
+
Balance sheet
net cash $653.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+19% above
Bullish
Price vs 50-day avg
+12% above
Bullish
RSI (14)
72 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
79% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $21 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +47 funds added
Insider flow
Accumulating
Net +$103.9K over 90 days · 50% sells
Short interest
Rising
16.03% of float · ▲ +7.6% MoM · 12.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $24 · 79%
52-wk high $28
vs 200-day avg +19%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNM
this stock
Immunome Inc.
|
$2.67B | +9.9% | -23.2% | — | 16.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNM | +21.7% | +19.2% | +15.5% | +11.4% | +9.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +20.3% | +20.4% | +7.4% | +11.7% | +0.7% |